Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : DNAP unlocking DNA coding -- Ignore unavailable to you. Want to Upgrade?

To: Olav who wrote (85)	2/20/2003 10:44:14 AM
From: Olav	Read Replies (1) \| Respond to of 95

DNAPrint Wins FAMRI Research Grant Thursday February 20, 9:43 am ET SARASOTA, Fla., Feb. 20 /PRNewswire-FirstCall/ -- DNAPrint (OTC Bulletin Board: DNAP - News; the "Company"), the world leader in the measurement of population structure for disease genetics, personalized medicine and forensics profiling, announced today that it has been awarded part of a 2-year grant worth $200,000 to study population genetic links between cervical disease and Environmental Tobacco Smoke (ETS). The award was made by the Flight Attendants Medical Research Institute (FAMRI), which was established as part of the $300M tobacco settlement finalized in 1997. The grant, titled "Genetic Susceptibility to Cervical Cancer in Second Hand Smokers", was written in collaboration with the University of Miami School of Medicine to mirror a study the Company and the University executed last year. That study was successful in identifying genetic markers of variable first-line response to paclitaxel/carboplatin chemotherapy, and led to the development of OVANOME, the Company's first chemopredictive product. The ultimate objective of the funded work is genomics-empowered disease prevention. There is considerable evidence that invasive cervical cancer arises from intraepithelial neoplasia (CIN) and that human papillomavirus (HPV) is involved in this initiation. However, HPV infection alone is clearly insufficient to fully explain CIN, and evidence suggests that ETS exposure is a contributing risk factor. The study funded today will employ DNAPrint's innovative approach for whole-genome screening (ADMIXMAP) to identify gene variants linked to this risk. A successful outcome could lead to a better understanding of the environmental and heritable mechanisms for CIN and, eventually, to the development of new preventative drugs and genomics-based tests. About FAMRI FAMRI, a nonprofit foundation, was created as part of the 1997 settlement between flight attendants and tobacco companies to study smoking-related illnesses. Almost five years after the tobacco industry agreed to pay $300 million to start a research foundation in order to settle a landmark lawsuit brought on behalf of thousands of flight attendants, the new Flight Attendant Medical Research Institute has just awarded its first 38 grants totaling $20 million to both individuals and organizations. FAMRI is supported by the Action on Smoking and Health (ASH), which is a 31-year-old national legal-action antismoking and nonsmokers' rights organization entirely supported by tax-deductible contributions. About DNAPrint genomics, Inc. DNAPrint genomics Inc. was founded by a team of scientists with research and commercial experience in high-level mathematical modeling, programming and molecular genetics. Using proprietary human genome research methods, the Company develops chemopredictive tests for matching patients with drugs based on their genetic constitution, discovers disease genes for the development of new drugs and develops new forensic genomics and recreational genomics testing products. The Company is traded on the Nasdaq OTC Bulletin Board under the ticker symbol: DNAP. For more information about the company, please visit www.dnaprint.com. All statements in this press release that are not historical are forward- looking statements within the meaning of Section 21E of the Securities Exchange Act as amended. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based. Media and Press Contacts Carrie Castillo DNAPrint genomics, Inc. Director, Marketing Communications castillo@dnaprint.com or Phil Brooks (941) 366-3400 Policy - Terms of Service - Ad Feedback Copyright © 2003 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.